Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
by Zacks Equity Research
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 Stocks to Buy for Attractive Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
by Zacks Equity Research
Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.
4 Must-Buy Stocks for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
by Zacks Equity Research
Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why
by Zacks Equity Research
Protagonist Therapeutics (PTGX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
by Zacks Equity Research
Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.
Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 141.1% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 25.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going
by Zacks Equity Research
Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's What Could Help Protagonist Therapeutics (PTGX) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
by Zacks Equity Research
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
Protagonist (PTGX) Up on Positive Results From FRONTIER Study
by Zacks Equity Research
Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.
Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.